See the DrugPatentWatch profile for ruxolitinib

After conducting a thorough search, I was unable to find specific information regarding the excipients in Apotex's formulation of Ruxolitinib. However, Ruxolitinib is a medication that is used to treat certain types of blood cancer and bone marrow disorders, and it is available under the brand name Jakafi in the United States [1].

Excipients are inactive substances that are included in a medication to improve its stability, shelf life, or administration. They can include a wide range of substances, such as binders, fillers, disintegrants, coatings, and preservatives [2].

According to DrugPatentWatch.com, Apotex holds several patents related to Ruxolitinib, including patents for methods of treatment, formulations, and combinations with other drugs [3]. However, the specific excipients used in Apotex's Ruxolitinib formulation are not disclosed in these patents.

It is worth noting that the exact composition of a medication, including its excipients, can vary depending on the manufacturer and the specific formulation. Therefore, it is always important to consult the package insert or contact the manufacturer for the most up-to-date and accurate information.

In summary, while I was unable to find specific information regarding the excipients in Apotex's Ruxolitinib formulation, it is important to consult the package insert or contact the manufacturer for the most accurate information.

Sources:

1. Mayo Clinic. Ruxolitinib (Oral Route) Side Effects. <https://www.mayoclinic.org/drugs-supplements/ruxolitinib-oral-route/side-effects/drg-20066133?p=1>
2. National Center for Biotechnology Information. Excipients. <https://www.ncbi.nlm.nih.gov/books/NBK538152/>
3. DrugPatentWatch.com. Ruxolitinib. <https://www.drugpatentwatch.com/drugs/ruxolitinib>